GENVEC –

Gaithersburg, Md.

Went public 12/12/00 at $9.50 per share

Filing Range: 4.0 million shares @ $11 to $12

Shares Outstanding: 17.8 million shares

Underwriters: J.P. Morgan & Co./A.G. Edwards & Sons Inc./UBS Warburg

Company Counsel: Arnold & Porter

Manager Counsel: Davis Polk & Wardwell

Auditor: KPMG LLP

The Company:

Develops in vivo delivery of human genes utilizing adenoviruses for the treatment of genetic and acquired diseases. The company attempts to treat genetic or acquired diseases by delivering informational segments of DNA directly into cells – via viral vectors – where they provide precise instructions for the cell to produce proteins that will correct or regulate the disease. The company is also developing product candidates and technologies for other applications, including vascular damage, oncology, and eye disease.

Venture Backers:

Hillman Ventures Inc.

Canaan Partners

Highland Capital Partners

Financing Rounds

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 04/01/1993 1 Early Stage 11320.0

2 07/01/1995 2 Early Stage 21065.0

3 01/01/1997 1 Expansion 1000.0

4 05/01/1997 1 Expansion 1000.0

5 07/01/1997 1 Expansion 2000.0

6 08/02/1997 1 Expansion 7000.0

7 10/02/1997 1 Expansion 5000.0

8 06/01/1999 1 Expansion 7000.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $16.9

Net Income: (1.9)